1. Home
  2. TRDA vs KF Comparison

TRDA vs KF Comparison

Compare TRDA & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.73

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

N/A

Current Price

$50.20

Market Cap

276.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
KF
Founded
2016
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
276.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TRDA
KF
Price
$4.73
$50.20
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $19.00
N/A
AVG Volume (30 Days)
★ 419.6K
18.7K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $25,421,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$550.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.11
$32.91
52 Week High
$16.45
$81.94

Technical Indicators

Market Signals
Indicator
TRDA
KF
Relative Strength Index (RSI) 45.06 37.71
Support Level $4.18 $50.45
Resistance Level $5.13 $59.05
Average True Range (ATR) 0.46 1.77
MACD 0.08 -0.34
Stochastic Oscillator 48.57 24.22

Price Performance

Historical Comparison
TRDA
KF

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, including equity securities, of Korean companies. Its portfolio consists of companies from different sectors such as auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.

Share on Social Networks: